BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
US |
|
I
|
ImpediMed Ltd
OTC:IPDQF
|
AU |
|
Andrea Electronics Corp
OTC:ANDR
|
US |
|
O
|
ODTech
KOSDAQ:080520
|
KR |
|
S
|
Solargiga Energy Holdings Ltd
XMUN:3FV
|
HK |
|
B
|
Blackstone Mortgage Trust Inc
F:079A
|
US |
|
Oaktree Specialty Lending Corp
F:FFC0
|
US |
|
I
|
Indofood CBP Sukses Makmur Tbk PT
XMUN:48I
|
ID |
|
A
|
Amgen Inc
BMV:AMGN
|
US |
|
S
|
Sumitomo Heavy Industries Ltd
DUS:SSM1
|
JP |
|
T
|
Tiger Brands Ltd
JSE:TBS
|
ZA |
Intrinsic Value
Is BCRX undervalued or overvalued?
See the intrinsic value estimate for BioCryst Pharmaceuticals Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
BCRX looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with BCRX’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What BioCryst Pharmaceuticals Does
BioCryst Pharmaceuticals is a biotechnology company that makes medicines for rare diseases, with a strong focus on hereditary angioedema, a genetic condition that causes repeated swelling attacks. Its main marketed product is Orladeyo, an oral preventive treatment that patients take long term. The company also develops other drug candidates for rare immune and inflammatory disorders, but its business is built around selling specialty medicines rather than broad consumer health products.
- Headquarters
- United States of America US
- Employees
- 435
- IPO date
- Mar 4, 1994
Revenue & Expenses Breakdown
BioCryst Pharmaceuticals Inc
Earnings Waterfall
BioCryst Pharmaceuticals Inc
The intrinsic value for BioCryst Pharmaceuticals Inc (BCRX) under the Base Case is hidden USD.
Compared with the current market price of 7.895 USD, the stock appears hidden.